STM 434: Preliminary Phase I data

Preliminary data from 22 patients with advanced solid tumors in a 3-part, open-label, dose-escalation, U.S. Phase I trial showed that 0.25,

Read the full 210 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE